Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme

The approvals of nintedanib and pirfenidone changed the treatment paradigm in idiopathic pulmonary fibrosis (IPF), and increased our understanding of the underlying disease mechanisms. Nonetheless, many challenges and unmet needs remain in the management of patients with IPF and other progressive fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Valenzuela, Claudia, Torrisi, Sebastiano Emanuele, Kahn, Nicolas, Quaresma, Manuel, Stowasser, Susanne, Kreuter, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945404/
https://www.ncbi.nlm.nih.gov/pubmed/31906942
http://dx.doi.org/10.1186/s12931-019-1269-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945404/
https://www.ncbi.nlm.nih.gov/pubmed/31906942
http://dx.doi.org/10.1186/s12931-019-1269-6

Ejemplares similares